Praxis Precision (PRAX) Stock: Relutrigine FDA Review Impact
Praxis Precision Medicines Sees Valuation Surge Following FDA Priority Review for Relutrigine Shares of Praxis Precision Medicines (NASDAQ: PRAX) experienced a significant jump on Friday, climbing over 13% in intraday trading, following the Food and Drug Administration’s (FDA) acceptance and priority review designation for its new drug application (NDA) for relutrigine. This promising development centers … Read more